Side Effects of Talz (Ixekizumab)
Talz (ixekizumab) is generally well-tolerated, but the most common side effects include infections and injection-site reactions. 1
Common Side Effects
- Infections: The most frequent adverse events of special interest with Talz are infections 1
- Injection-site reactions: These are common and typically occur at the location where the medication is administered 1
- Gastrointestinal effects: May include nausea and other digestive disturbances 2
Serious Side Effects
- Inflammatory response: As an IL-17A inhibitor, Talz can affect immune system function, potentially leading to inflammatory reactions 2, 3
- Respiratory issues: In rare cases, respiratory complications have been reported with biological therapies, though specific risk with Talz is low 2
- Hypersensitivity reactions: As with any monoclonal antibody, allergic reactions are possible 3
Monitoring and Precautions
- Infection screening: Patients should be evaluated for tuberculosis and other infections before starting therapy 2
- Ongoing monitoring: Regular assessment for signs of infection or other adverse effects is recommended throughout treatment 2
- Pregnancy considerations: Use during pregnancy should be carefully evaluated as safety data is limited 1
Tolerability Profile
- Talz has demonstrated a favorable tolerability profile in clinical trials with discontinuation rates due to adverse events similar to placebo 1
- The medication is generally well-tolerated in long-term treatment, with sustained efficacy reported up to 12 months with no significant side effects in some studies 4
Special Populations
- Patients with pre-existing conditions may require additional monitoring, particularly those with compromised immune systems 2
- The medication has been studied primarily in adults with plaque psoriasis, with evidence supporting its safety profile in this population 1